NephroGenex Inc. |
 |
Concept Development |
Lead Discovery |
Lead Optimization |
Preclinical Development |
Phase I |
Phase II |
Phase III |
Launch |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Project: |
|
||||||||||||||||
NephroGenex Inc.
NephroGenex has completed Phase II trials with promising results using the company’s lead candidate product Pyridorin™. The targeted pharmacological mechanism involves pathogenic oxidative chemistries that are an important factor in kidney diseases such as diabetic nephropathy and acute renal failure.
| Contact: J Wesley Fox, CEO | +1 919 678 95 12| info@nephrogenex.com | http://www.nephrogenex.com/ |